BGPT: Author Review: Yi Yang

Fuel Your Discoveries

Quick Explanation Copied

Yi Yang — scientific strength snapshot

Based on the provided paper-level evidence summaries, Yi Yang’s work shows high mechanistic depth (structural biology, multi-omics integration, mechanistic immuno-oncology signaling) and repeated methodological rigor, but some themes recur: (i) limited or indirect translational validation, (ii) reliance on computational proxies in parts of the portfolio, and (iii) occasional reproducibility caveats and selection/heterogeneity risks common to high-throughput biology.

Long Explanation

Author Review: Yi Yang (evidence-grounded)

Evidence basis: the provided collection of Yi Yang–linked paper records and method/result summaries (including DOIs, sample sizes, and explicit limitation statements).

Portfolio-wide evidence patterns (from provided records)

This section visualizes only what is explicitly present in the provided research data (e.g., the given per-paper quality scores and extracted dataset descriptors).

Evidence strength & mechanistic themes (paper-by-paper)

Below, each claim is tied to at least one provided DOI record.

1) Cardiovascular immuno-metabolic subtyping (plasma proteomics → ML phenotypes)

Reports identifying two molecular subtypes (CDVR and ITMD) inside “poor coronary collateral circulation” using plasma DIA proteomics plus clinical features, with external validation using MIMIC-IV.
Reported performance includes high AUCs for subtype discrimination and a separate binary task between CDVR and ITMD, alongside SHAP interpretability.
Key scientific caution: the record itself flags that this is observational and that confounding by therapies may not be fully excluded, with discovery cohort size described as modest and follow-up described as <1 year.

2) Senescence multiomic atlas across primary cell types (SenCat)

Reports building a multiomic catalog of senescence signatures across 14 primary human cell types and >30 senescence paradigms, and emphasizes that it does not claim universal markers.
Reports multiple layers of validation (external IMR-90; in vivo doxorubicin-induced senescence; and additional aging datasets).
Scientific caution: the record acknowledges transcript–protein discordance (no single molecule consistently altered) and limitations from timepoint resolution and cross-context generalization.

3) Structural biology & mechanism from cryo-EM (Euglena PSI-LHCE)

Reports a 2.23 Å cryo-EM reconstruction for Euglena gracilis PSI-LHCE, including pigment/cofactor composition and antenna subunit organization.
Reports energy-transfer dynamics with a dominant trapping time and high quantum efficiency, and discusses “mosaic green/red” evolutionary organization.
Scientific caution: the record notes weak density for some antenna elements and reliance on AlphaFold-based modeling in parts of antenna protein modeling.

Method-type distribution (how the evidence is produced)

This figure groups the provided paper records by the recorded evidence style (mechanistic experiment vs computational inference vs review).

Cross-cutting critique (what looks strong vs what stays uncertain)

Strength: mechanistic coupling (not just correlation) appears repeatedly. Examples in the provided records include structural/pigment-specific mechanistic claims (PSI-LHCE cryo-EM) , and mechanistic RNA/protein regulation with targeted assays (e.g., EZH2→YTHDF1→m6A→translation logic) .
Strength: explicit acknowledgment of heterogeneity (senescence) and multi-context constraints. SenCat explicitly states lack of universal markers while still producing ML-derived scores and validating across contexts .
Strength: computational-method papers show typical “model validation” scaffolding. For example, scMDCF record describes evaluation against baselines and reporting improved clustering/integration while mitigating batch effects (note: see limitations below for interpretability concerns).
Recurring uncertainty: translational generalization and observational confounding. The CTO proteomics phenotyping record is observational and flags therapy confounding and modest discovery cohort size .
Reproducibility caveat: some portfolio segments rely on proxies/limited validation. For the gastric immune transcriptomic prognosis model record, it flags platform heterogeneity, incomplete clinical variables in cohorts, retrospective design, and possible residual confounding .
One particularly strict caution: predictive biomarker models may need stronger external validation. The TCRβ signature for adjuvant EGFR-TKI benefit record explicitly notes retrospective single-cohort limitations, modest sample size, and lack of external validation in the summary .
Review paper section has lower reproducibility by nature. The viral oncogenesis item is labeled as narrative review with no new dataset; reproducibility and evidence hierarchy are therefore limited .

What would most reduce uncertainty?

Information that would falsify or materially change these conclusions includes: (i) independent external cohorts with harmonized preprocessing for biomarker/phenotype models (CTO, ITPG, TCR signature) ; (ii) additional mechanistic perturbation experiments for pathway claims where current evidence is more proxy-based (e.g., multiomic crosstalk interpretations in computational-heavy works) .

Utility to a BGPT user

Your provided evidence suggests Yi Yang’s strengths cluster around: (a) multi-omic integration with explicit limitations, (b) translationally-oriented biomarker modeling (with standard caveats), and (c) mechanistic structural biology with experimentally grounded readouts.

Feedback:

Updated: March 25, 2026